Bio-Path Holdings Faces Nasdaq Delisting Warning

TL;DR

BPTH got a delisting warning from Nasdaq, stock might get booted.

AI Summary

Bio-Path Holdings, Inc. (BPTH) filed an 8-K on March 13, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is facing potential delisting from the Nasdaq Capital Market due to not meeting certain requirements.

Why It Matters

This filing indicates Bio-Path Holdings may be delisted from the Nasdaq, which could significantly impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A delisting notice from a major exchange like Nasdaq poses a significant risk to the company's continued trading and investor accessibility.

Key Players & Entities

• Bio-Path Holdings, Inc. (company) — Registrant
• Nasdaq Capital Market (company) — Exchange where the company is listed
• 0001558370-24-003118 (other) — Accession Number for the filing
• March 12, 2024 (date) — Earliest event date reported
• March 13, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
• $2,500,000 — holders' equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq C

Filing Documents

• bpth-20240312x8k.htm (8-K) — 35KB
• 0001558370-24-003118.txt ( ) — 152KB
• bpth-20240312.xsd (EX-101.SCH) — 3KB
• bpth-20240312_lab.xml (EX-101.LAB) — 16KB
• bpth-20240312_pre.xml (EX-101.PRE) — 10KB
• bpth-20240312x8k_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 12, 2024, Bio-Path Holdings, Inc. (the "Company") received a deficiency letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum stockholders' equity requirement of at least $2,500,000 for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). The Letter has no effect on the listing of the Company's common stock at this time, and the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "BPTH." In accordance with Nasdaq Listing Rule 5810(c)(2)(A), the Company has 45 calendar days, or until April 26. 2024, to submit a plan to Nasdaq to regain compliance (the "Compliance Plan") with the Stockholders' Equity Requirement. If the Compliance Plan is accepted, Nasdaq can grant an extension of up to 180 days from the date of the Letter for the Company to evidence compliance. If the Compliance Plan is not accepted, Nasdaq could provide written notification to the Company that its common stock may be delisted. At that time, the Company may appeal Nasdaq's delisting determination to a Nasdaq Hearings Panel (the "Panel"). If the Company timely appeals, it would remain listed pending the Panel's decision. There can be no assurance that, if the Company does appeal the delisting determination by Nasdaq to the Panel, such appeal would be successful. The Company is considering available options to regain compliance with the Stockholders' Equity Requirement. However, there can be no assurance that the Company will be successful in developing the Compliance Plan, that the Compliance Plan will be accepted by Nasdaq, or even if it is accepted, that the Company will ultimately be able to regain compliance with the Stockholders' Equity

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: March 13, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR